Executive Vice President, Chief Legal Officer · Olema Pharmaceuticals, Inc. (OLMA)

John Moriarty

FY2020 is the first fiscal year CompBrief holds for John Moriarty as a named executive officer of Olema Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$3,016,961

Salary $125,556

4th of 4 named executive officers at Olema Pharmaceuticals by FY2020 total.

4 named officers on file for Olema Pharmaceuticals, FY2020

John Moriarty’s pay file — $29

  • 1 fiscal year of pay, line by line
  • OLMA’s disclosed peer group of 28 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Olema Pharmaceuticals’s whole pay program stands against its peers

  • Olema Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on OLMA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2021 (DEF 14A).

Free

Get John Moriarty’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

John Moriarty compensation by year

Olema Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Olema Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$125,556
Bonus$0
Option awards$2,833,750
Non-equity incentive$57,656
Pension and deferred compensation$0
All other$0
Total$3,016,961

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Olema Pharmaceuticals, Inc. DEF 14A filed April 27, 2021, accession 0001558370-21-004911, and prior-year filings.

How this page was built: the Olema Pharmaceuticals, Inc. filed document, accession 0001558370-21-004911. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option161,406—$19.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Olema Pharmaceuticals, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Olema Pharmaceuticals’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Sean BohenPresident and Chief Executive Officer$10,598,498
Cyrus HarmonChief Technology Officer and former Chief Executive Officer (4)$3,976,890
Peter KushnerChief Scientific Officer$3,024,715
John Moriarty · this pageExecutive Vice President, Chief Legal Officer$3,016,961

The full Olema Pharmaceuticals compensation record

free company brief

This page is one person within Olema Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Olema Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Olema Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

John Moriarty's compensation dossier · One-time report. No refunds.